Epidermal Growth Factor Receptor Mutations in the Blood of Patients With Advanced Non-Small Cell Lung Cancer

Study of Mutations of Epidermal Growth Factor Receptor in the Blood of Patients With Advanced Non Small Cell Lung Cancer

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00899756

Enrollment

Registered

2009-05-12

Start date

2006-06-30

Completion date

2016-12-31

Last updated

2019-02-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Cancer

Keywords

recurrent non-small cell lung cancer, stage IIIA non-small cell lung cancer, stage IIIB non-small cell lung cancer, stage IV non-small cell lung cancer

Brief summary

RATIONALE: Collecting and storing samples of blood from patients with cancer to study in the laboratory may help doctors learn more about changes that may occur in DNA and identify biomarkers related to cancer. PURPOSE: This laboratory study is looking at epidermal growth factor receptor mutations in the blood of patients with advanced non-small cell lung cancer.

Detailed description

OBJECTIVES: * Determine if epidermal growth factor receptor (EGFR) mutation exists in the peripheral blood of patients with advanced non-small cell lung cancer (NSCLC). * Estimate the frequency of EGFR mutation in these patients. * Correlate the presence of EGFR mutation in blood with EGFR mutation in primary or metastatic NSCLC tumor block. OUTLINE: Patients undergo blood collection for analysis of epidermal growth factor receptor mutation by DNA sequencing. PROJECTED ACCRUAL: A total of 50 patients will be accrued for this study.

Interventions

GENETICmolecular diagnostic method

GENETICmutation analysis

Study design

Observational model

OTHER

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

DISEASE CHARACTERISTICS: * Histologically or cytologically confirmed advanced non-small cell lung cancer * Must have available tumor tissue block PATIENT CHARACTERISTICS: * Not specified PRIOR CONCURRENT THERAPY: * Not specified

Design outcomes

Primary

Measure	Time frame	Description
Existence of epidermal growth factor receptor (EGFR) mutations in peripheral blood	Day 1	—
Frequency of EGFR mutation	Day 1	Number of participants with EGFR mutation in tissue and plasma.
Number of participants with EGFR mutation in peripheral blood and in tumor tissue.	Day 1	—

Countries

Singapore

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026